Commercial Excellence in Rare Diseases and Orphan Drugs

Commercial Excellence in Rare Diseases and Orphan Drugs

Code: FW-20150609 | Published: Jun-2015 | Pages: - | FirstWord
Price :

* Required Fields



Developing therapies for orphan diseases is attracting much industry interest with the promise of profits. But what are the specific R&D, regulatory, stakeholder and market access issues you need to understand and practically address?

Commercial Excellence in Rare Diseases and Orphan Drugs is a highly-detailed report for industry management who must evaluate, plan, execute, manage and deliver profit from orphan drug programmes. Enriched with case studies, the report reveals the real-world experience and actionable insights of eight senior industry experts who possess a deep knowledge of the challenging and highly-demanding operating environment for orphan drug development and commercialisation.

Gain Answers to Key Questions

- How can patients and patient advocacy groups play an enhanced role throughout a products development cycle from research funding to market access?
- Why is early engagement with payers and KOLs critical in ensuring wide market access and uptake?
- To what extent is the accurate assessment of unmet clinical need and establishing potential patient population critical and what are the benchmarks?
- With approximately 7,000 identified orphan diseases, how do you select research targets for development?
- Clinical trial design and recruitment are challenges for orphan drug developers: what needs to be taken into account and how have companies approached this?
- Orphan drug regulation is relatively relaxed, but what more could regulators do and how can you influence them?
- Small/Big pharma collaborations: when is the optimum time for engagement and what can each learn from each other?

Top Benefits

- Understand how patient support is a must-have for industry and identify the areas where they are most influential
- Formulate communication strategies to ensure wide clinical buy-in and support
- Address effectively the anxieties of payers who must justify orphan drug spend in their budgets
- Examine critical orphan drug candidate selection and overcome challenges of designing and conducting clinical trials
- Understand what is considered to be commercial excellence for orphan drugs and what are the hurdles for success
- Gain insight into current company structures for orphan drugs and the way in which rare disease teams should be structured in order to maximise commercial success
- Understand the regulatory structures that determine orphan drug research/approval and learn where and how regulators can be influenced

Key Takeaways

- Orphan drugs offer a positive opportunity for Pharma, but companies must be realistic about their potential and the challenges - old models of assessment used for drugs targeting large patient populations are not fit for purpose
- Engagement with key stakeholders at an early stage is critical to ultimate commercial success
- Patient Groups, more than any other area, are critical to success and hugely influential in realising a products commercial potential
- Orphan drugs are often very expensive: make your case to payers, and make it early to ensure buy in
- Identifying appropriate research candidates for late phase investment requires a clear understanding of unmet needs and patient population - and how you will access them
- Regulators may look positively on orphan drug applications but there are still challenges to overcome
- The internal organisation of orphan drug teams varies and the assessment of different models is critical

Report Features - Not Available Elsewhere

- Knowledgeable and detailed insights and opinions of eight industry experts working daily in developing and commercialising orphan disease drugs in the US and Europe

- Extensive case studies demonstrating different approaches and experiences for ensuring commercial effectiveness

- Critical insights for corporate, research, planning, marketing and communications management

Experts Interviewed

- Business Unit Head, Rare diseases, Top 10 pharmaceutical company

- Senior Director, Top 10 pharmaceutical company

- Marketing Director, Mid-size European pharmaceutical company

- Sales Director, European pharmaceutical company

- Senior Product Manager, Top 10 pharmaceutical company

- Director, Rare disease pharmaceutical company

- Marketing Director, Top 10 pharmaceutical company

- Marketing Director, Top 10 pharmaceutical company

About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence

- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients